Wednesday, July 8, 2026

Patent intelligence · US

US 11713292

Treatment of cataplexy

granted A61KA61K31/27A61K31/325A61K45/06
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 17
Applicant portfolio 162
Patent details — US 11713292
Jurisdiction
US
Status
granted
Grant date
Aug 1, 2023
Expiration
Jul 27, 2043
Applicant
AXSOME MALTA LTD.
Claims
18
CPC classes
A61K, A61K31/27, A61K31/325, A61K45/06
View on Google Patents ↗

Quick answer

US 11713292 (Treatment of cataplexy) is held by AXSOME MALTA LTD.. Status: granted. Granted Aug 1, 2023. Expires Jul 27, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
AXSOME MALTA LTD.
Grant date
Expiration
Claims
18
CPC classes
A61K, A61K31/27, A61K31/325, A61K45/06, A61K9/0053, A61K9/20

More from AXSOME MALTA LTD.

Related pharmaceutical patents in our USPTO index.

  1. US 12390419

    Formulations of (R)-2-amino-3-phenylpropyl carbamate

    AXSOME MALTA LTD. · Expires Aug 14, 2045

    granted
  2. US 12384743

    Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereof

    AXSOME MALTA LTD. · Expires Aug 7, 2045

    granted
  3. US 12370196

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. · Expires Jul 24, 2045

    granted
  4. US 12357640

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. · Expires Jul 10, 2045

    granted
  5. US 12357697

    Pharmaceutical compositions comprising bupropion and cysteine

    AXSOME THERAPEUTICS, INC. · Expires Jul 10, 2045

    granted
  6. US 12318362

    Methods of providing solriamfetol therapy to subjects with impaired renal function

    AXSOME MALTA LTD. · Expires May 29, 2045

    granted
  7. US 12268693

    Pharmaceutical compositions comprising a tolfenamic acid

    AXSOME THERAPEUTICS, INC. · Expires Apr 3, 2045

    granted
  8. US 12263145

    Methods of administering solriamfetol to lactating women

    AXSOME MALTA LTD. · Expires Mar 27, 2045

    granted

Frequently asked questions

What is US patent 11713292?

US 11713292 (Treatment of cataplexy) is held by AXSOME MALTA LTD.. Status: granted. Granted Aug 1, 2023. Expires Jul 27, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11713292?

AXSOME MALTA LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 162 pharmaceutical patents for this assignee.

When does US 11713292 expire?

Our index shows an expiration date of Jul 27, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.